Literature DB >> 17675263

New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Tatsuya Kawaguchi1, Hideki Nakakuma.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is caused by the clonal expansion of hematopoietic stem cells with mutations of the phosphatidylinositol glycan-class A gene (PIGA). PNH clones then fail to generate glycosylphosphatidylinositol (GPI) or to express a series of GPI-linked membrane proteins including complement-regulatory proteins, resulting in complement-mediated intravascular hemolysis and thrombosis. Bone marrow failure is another characteristic feature of PNH. It is currently considered that immune-mediated injury of hematopoietic cells is implicated in PNH marrow failure as well as in aplastic anemia, a well-known PNH-related disorder. There is increasing evidence that the autoimmune attack allows PNH clones to selectively survive in the injured marrow, leading to clinical manifestations characteristic of PNH. As candidate molecules that trigger the immune attack on marrow cells, stress-inducible membrane proteins and Wilms' tumor protein WT1 have been proposed. Among the stress-inducible proteins, GPI-linked proteins, such as cytomegalovirus glycoprotein UL16-binding protein, are distinct candidates that not only induce immune attack, but also allow PNH clones to survive the attack. Here, we overview the current understanding of the molecular pathogenesis of bone marrow failure in PNH.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675263     DOI: 10.1532/IJH97.07029

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  81 in total

1.  Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis.

Authors:  H Wang; T Chuhjo; H Yamazaki; S Shiobara; M Teramura; H Mizoguchi; S Nakao
Journal:  Eur J Haematol       Date:  2001-03       Impact factor: 2.997

Review 2.  The problem of clonality in aplastic anemia: Dr Dameshek's riddle, restated.

Authors:  N S Young
Journal:  Blood       Date:  1992-03-15       Impact factor: 22.113

3.  Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology.

Authors:  G Socié; J Y Mary; A de Gramont; B Rio; M Leporrier; C Rose; P Heudier; H Rochant; J Y Cahn; E Gluckman
Journal:  Lancet       Date:  1996-08-31       Impact factor: 79.321

4.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.

Authors:  D E Dunn; P Tanawattanacharoen; P Boccuni; S Nagakura; S W Green; M R Kirby; M S Kumar; S Rosenfeld; N S Young
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

5.  Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene.

Authors:  G Tremml; C Dominguez; V Rosti; Z Zhang; P P Pandolfi; P Keller; M Bessler
Journal:  Blood       Date:  1999-11-01       Impact factor: 22.113

6.  Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria.

Authors:  R Chen; S Nagarajan; G M Prince; U Maheshwari; L W Terstappen; D R Kaplan; S L Gerson; J M Albert; D E Dunn; H M Lazarus; M E Medof
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 7.  Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria.

Authors:  D J Araten; D Swirsky; A Karadimitris; R Notaro; K Nafa; M Bessler; H T Thaler; H Castro-Malaspina; B H Childs; F Boulad; M Weiss; N Anagnostopoulos; A Kutlar; D G Savage; R T Maziarz; S Jhanwar; L Luzzatto
Journal:  Br J Haematol       Date:  2001-11       Impact factor: 6.998

8.  Development of the glycosylphosphatitylinositol-anchoring defect characteristic for paroxysmal nocturnal hemoglobinuria in patients with aplastic anemia.

Authors:  J Schubert; H G Vogt; M Zielinska-Skowronek; M Freund; J P Kaltwasser; D Hoelzer; R E Schmidt
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

9.  Characterization of the hematopoietic defect in paroxysmal nocturnal hemoglobinuria.

Authors:  J G Moore; R K Humphries; M M Frank; N Young
Journal:  Exp Hematol       Date:  1986-03       Impact factor: 3.084

10.  Natural history of paroxysmal nocturnal hemoglobinuria.

Authors:  P Hillmen; S M Lewis; M Bessler; L Luzzatto; J V Dacie
Journal:  N Engl J Med       Date:  1995-11-09       Impact factor: 91.245

View more
  5 in total

1.  Ex vivo expansion and long-term hematopoietic reconstitution ability of sorted CD34+CD59+ cells from patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Juan Xiao; Bing Han; Yong-Ji Wu; Yu-ping Zhong; Wan-ling Sun
Journal:  Int J Hematol       Date:  2010-06-25       Impact factor: 2.490

2.  (2S,4R)-4-[18F]Fluoroglutamine as a PET Indicator for Bone Marrow Metabolism Dysfunctional: from Animal Experiments to Clinical Application.

Authors:  Hua Zhu; Fei Liu; Yan Zhang; Jianhua Yang; Xiaoxia Xu; Xiaoyi Guo; Teli Liu; Nan Li; Lin Zhu; Hank F Kung; Zhi Yang
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

3.  B-Cell-Rich T-Cell Lymphoma Associated with Epstein-Barr Virus-Reactivation and T-Cell Suppression Following Antithymocyte Globulin Therapy in a Patient with Severe Aplastic Anemia.

Authors:  Nobuyoshi Hanaoka; Shogo Murata; Hiroki Hosoi; Aiko Shimokado; Toshiki Mushino; Kodai Kuriyama; Kazuo Hatanaka; Akinori Nishikawa; Miwa Kurimoto; Takashi Sonoki; Yasuteru Muragaki; Hideki Nakakuma
Journal:  Hematol Rep       Date:  2015-09-23

Review 4.  Ocular manifestations of idiopathic aplastic anemia: retrospective study and literature review.

Authors:  Ahmad M Mansour; Jong Wook Lee; Seung Ah Yahng; Kyu Seop Kim; Maha Shahin; Nelson Hamerschlak; Rubens N Belfort; Shree K Kurup
Journal:  Clin Ophthalmol       Date:  2014-04-17

5.  Recurrent aseptic meningitis with PIGT mutations: a novel pathogenesis of recurrent meningitis successfully treated by eculizumab.

Authors:  Michi Kawamoto; Yoshiko Murakami; Taroh Kinoshita; Nobuo Kohara
Journal:  BMJ Case Rep       Date:  2018-09-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.